BridgeBio Oncology Reports Q4 2025 Financial Results and R&D Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy BBOT?
Source: seekingalpha
- Financial Performance: BridgeBio Oncology reported a GAAP EPS of -$0.49 for Q4 2025, indicating challenges in profitability; however, with cash and equivalents totaling $425.5 million, the company expects to sustain operations into 2028.
- R&D Expense Increase: R&D expenses surged to $38.1 million in Q4 2025 from $19.5 million in Q4 2024, primarily driven by rising clinical trial and manufacturing costs for BBO-8520, BBO-11818, and BBO-10203, reflecting the company's commitment to drug development.
- Administrative Costs Rise: General and administrative expenses reached $5.3 million in Q4 2025, up from $2.3 million in Q4 2024, indicating adjustments related to BBOT's standalone operations and the initiation of its de-SPAC transaction.
- Net Loss Widening: The net loss for Q4 2025 was $38.8 million, nearly doubling from $19.7 million in Q4 2024, highlighting the financial pressures faced by the company as it expands its R&D and operational activities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBOT
Wall Street analysts forecast BBOT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.970
Low
18.00
Averages
22.83
High
27.00
Current: 8.970
Low
18.00
Averages
22.83
High
27.00
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BridgeBio Appoints New CEO and COO
- Executive Appointments: BridgeBio Oncology Therapeutics has appointed Pedro J. Beltran as CEO and Idan Elmelech as COO effective April 20, 2026, aiming to strengthen the company's leadership and strategic direction.
- Experienced Leadership: Beltran brings approximately 20 years of oncology R&D experience from previous roles at Amgen and UNITY Biotechnology, which is expected to provide valuable industry insights and drive innovation within the company.
- Former CEO's Advisory Role: Former CEO Eli Wallace will continue as a Senior Adviser, ensuring strategic consistency during the transition and leveraging his extensive experience to guide the new leadership team.
- Financial Performance: BridgeBio Oncology reported a GAAP EPS of -$0.49, and despite facing financial challenges, the company is actively advancing its KRAS revolution plan, demonstrating confidence in future growth prospects.
See More
BBOT Appoints New CEO and COO to Drive Growth
- Leadership Transition: Pedro J. Beltran, PhD, appointed as CEO on April 20, 2026, brings over 20 years of oncology drug development experience to steer BBOT's strategic growth in RAS and PI3Kα malignancies.
- Operational Management Enhancement: Idan Elmelech takes on the role of COO, overseeing finance, corporate strategy, and business development, aiming to accelerate the expansion of BBOT's clinical assets through optimized operational efficiency.
- Board Support: Neil Kumar, PhD, appointed as Executive Chairman, will guide the company into its next development phase, emphasizing that the leadership change will enhance the company's execution capabilities and strategic precision in clinical trials.
- Former CEO's Continued Contribution: Former CEO Eli Wallace, PhD, will serve as a Senior Adviser, leveraging his scientific expertise to support BBOT's projects, ensuring the company's sustained development under new leadership.
See More
FDA Grants Fast Track Designation to BBO-11818 for Pancreatic Cancer
- Fast Track Designation: BridgeBio Oncology Therapeutics' BBO-11818 has received Fast Track designation from the FDA for treating adults with advanced KRAS-mutant pancreatic ductal adenocarcinoma, marking a significant advancement in cancer therapy.
- Preliminary Data Support: Preliminary data released in January 2026 indicated that BBO-11818 monotherapy showed a confirmed partial response in pancreatic cancer patients, highlighting its potential efficacy in treatment.
- Observed Anti-Tumor Activity: Anti-tumor activity was observed across various dose levels and tumor types, particularly with tumor reductions at higher doses, indicating a favorable safety profile and offering new treatment options for patients.
- Clinical Trial Progress: BBO-11818 is currently being evaluated in the Phase I KONQUER-101 trial for patients with locally advanced unresectable or metastatic KRAS-mutant solid tumors, with updated data expected in the second half of 2026 to further validate its clinical effectiveness.
See More
BridgeBio Oncology Receives FDA Fast Track Designation for BBO-11818
- FDA Fast Track Designation: BridgeBio Oncology Therapeutics announced that its candidate BBO-11818 for advanced KRAS-mutant pancreatic ductal adenocarcinoma has received Fast Track designation from the US FDA, which is expected to accelerate its clinical development and enhance market competitiveness.
- Clinical Trial Progress: BBO-11818 is currently in the KONQUER-101 trial, having enrolled patients with locally advanced unresectable or metastatic KRAS-mutant solid tumors, demonstrating promising early clinical responses that could provide new treatment options for patients.
- Positive Preliminary Data: Preliminary data released in January indicated a confirmed partial response for BBO-11818, showcasing its strong activity in KRAS-mutant preclinical models, which may lay the groundwork for future clinical applications.
- Positive Market Reaction: Following the announcement, BridgeBio's stock rose approximately 8% in after-hours trading, reflecting investor optimism regarding the drug's potential, which could drive future financing and R&D investments for the company.
See More
BBOT Receives FDA Fast Track Designation for BBO-11818
- FDA Fast Track Designation: BBOT's BBO-11818 has received Fast Track designation from the FDA for its potential in treating advanced KRAS-mutant pancreatic ductal adenocarcinoma, which will expedite its development process to meet urgent patient needs for new therapies.
- Clinical Trial Progress: Currently evaluated in the KONQUER-101 trial, updated clinical data for BBO-11818 is expected in the second half of 2026, showcasing its anti-tumor activity and safety profile in KRAS-mutant tumors.
- Addressing Unmet Medical Needs: While KRASG12C inhibitors have shown clinical efficacy, there remains a significant unmet medical need for therapies targeting other KRAS mutations such as KRASG12D and KRASG12V, which BBO-11818 aims to address as a potent pan-KRAS inhibitor.
- Multiple Treatment Regimens: BBO-11818 is being evaluated not only as a monotherapy but also in combination with standard-of-care therapies and BBOT's RAS:PI3Kα inhibitor BBO-10203, demonstrating its potential across various treatment combinations and enhancing its market competitiveness.
See More
BBO-11818: New KRAS Inhibitor Shows Promising Potential
- Preclinical Data Release: BridgeBio Oncology Therapeutics (BBOT) published preclinical data on BBO-11818, demonstrating significant tumor growth inhibition in KRAS mutant models, particularly against KRASG12D and KRASG12V mutations, indicating its potential therapeutic value for KRAS-driven tumors.
- Combination Therapy Potential: BBO-11818 shows enhanced efficacy when used in combination with other anti-tumor agents, such as BBO-10203, suggesting its importance in future treatment regimens and the potential to reshape existing treatment landscapes.
- Clinical Trial Progress: Initial data from the KONQUER-101 trial indicate promising anti-tumor activity across various tumor types, including a 56% tumor reduction in a pancreatic cancer patient, with additional data expected in the second half of 2026.
- Selectivity and Resistance: BBO-11818 exhibits over 500-fold selectivity for KRAS compared to other RAS isoforms, highlighting its potential to overcome resistance mechanisms associated with existing KRAS inhibitors, potentially offering better tolerability and therapeutic outcomes for patients.
See More
BridgeBio Appoints New CEO and COO
- Executive Appointments: BridgeBio Oncology Therapeutics has appointed Pedro J. Beltran as CEO and Idan Elmelech as COO effective April 20, 2026, aiming to strengthen the company's leadership and strategic direction.
- Experienced Leadership: Beltran brings approximately 20 years of oncology R&D experience from previous roles at Amgen and UNITY Biotechnology, which is expected to provide valuable industry insights and drive innovation within the company.
- Former CEO's Advisory Role: Former CEO Eli Wallace will continue as a Senior Adviser, ensuring strategic consistency during the transition and leveraging his extensive experience to guide the new leadership team.
- Financial Performance: BridgeBio Oncology reported a GAAP EPS of -$0.49, and despite facing financial challenges, the company is actively advancing its KRAS revolution plan, demonstrating confidence in future growth prospects.
See More
BBOT Appoints New CEO and COO to Drive Growth
- Leadership Transition: Pedro J. Beltran, PhD, appointed as CEO on April 20, 2026, brings over 20 years of oncology drug development experience to steer BBOT's strategic growth in RAS and PI3Kα malignancies.
- Operational Management Enhancement: Idan Elmelech takes on the role of COO, overseeing finance, corporate strategy, and business development, aiming to accelerate the expansion of BBOT's clinical assets through optimized operational efficiency.
- Board Support: Neil Kumar, PhD, appointed as Executive Chairman, will guide the company into its next development phase, emphasizing that the leadership change will enhance the company's execution capabilities and strategic precision in clinical trials.
- Former CEO's Continued Contribution: Former CEO Eli Wallace, PhD, will serve as a Senior Adviser, leveraging his scientific expertise to support BBOT's projects, ensuring the company's sustained development under new leadership.
See More
FDA Grants Fast Track Designation to BBO-11818 for Pancreatic Cancer
- Fast Track Designation: BridgeBio Oncology Therapeutics' BBO-11818 has received Fast Track designation from the FDA for treating adults with advanced KRAS-mutant pancreatic ductal adenocarcinoma, marking a significant advancement in cancer therapy.
- Preliminary Data Support: Preliminary data released in January 2026 indicated that BBO-11818 monotherapy showed a confirmed partial response in pancreatic cancer patients, highlighting its potential efficacy in treatment.
- Observed Anti-Tumor Activity: Anti-tumor activity was observed across various dose levels and tumor types, particularly with tumor reductions at higher doses, indicating a favorable safety profile and offering new treatment options for patients.
- Clinical Trial Progress: BBO-11818 is currently being evaluated in the Phase I KONQUER-101 trial for patients with locally advanced unresectable or metastatic KRAS-mutant solid tumors, with updated data expected in the second half of 2026 to further validate its clinical effectiveness.
See More
BridgeBio Oncology Receives FDA Fast Track Designation for BBO-11818
- FDA Fast Track Designation: BridgeBio Oncology Therapeutics announced that its candidate BBO-11818 for advanced KRAS-mutant pancreatic ductal adenocarcinoma has received Fast Track designation from the US FDA, which is expected to accelerate its clinical development and enhance market competitiveness.
- Clinical Trial Progress: BBO-11818 is currently in the KONQUER-101 trial, having enrolled patients with locally advanced unresectable or metastatic KRAS-mutant solid tumors, demonstrating promising early clinical responses that could provide new treatment options for patients.
- Positive Preliminary Data: Preliminary data released in January indicated a confirmed partial response for BBO-11818, showcasing its strong activity in KRAS-mutant preclinical models, which may lay the groundwork for future clinical applications.
- Positive Market Reaction: Following the announcement, BridgeBio's stock rose approximately 8% in after-hours trading, reflecting investor optimism regarding the drug's potential, which could drive future financing and R&D investments for the company.
See More
BBOT Receives FDA Fast Track Designation for BBO-11818
- FDA Fast Track Designation: BBOT's BBO-11818 has received Fast Track designation from the FDA for its potential in treating advanced KRAS-mutant pancreatic ductal adenocarcinoma, which will expedite its development process to meet urgent patient needs for new therapies.
- Clinical Trial Progress: Currently evaluated in the KONQUER-101 trial, updated clinical data for BBO-11818 is expected in the second half of 2026, showcasing its anti-tumor activity and safety profile in KRAS-mutant tumors.
- Addressing Unmet Medical Needs: While KRASG12C inhibitors have shown clinical efficacy, there remains a significant unmet medical need for therapies targeting other KRAS mutations such as KRASG12D and KRASG12V, which BBO-11818 aims to address as a potent pan-KRAS inhibitor.
- Multiple Treatment Regimens: BBO-11818 is being evaluated not only as a monotherapy but also in combination with standard-of-care therapies and BBOT's RAS:PI3Kα inhibitor BBO-10203, demonstrating its potential across various treatment combinations and enhancing its market competitiveness.
See More
BBO-11818: New KRAS Inhibitor Shows Promising Potential
- Preclinical Data Release: BridgeBio Oncology Therapeutics (BBOT) published preclinical data on BBO-11818, demonstrating significant tumor growth inhibition in KRAS mutant models, particularly against KRASG12D and KRASG12V mutations, indicating its potential therapeutic value for KRAS-driven tumors.
- Combination Therapy Potential: BBO-11818 shows enhanced efficacy when used in combination with other anti-tumor agents, such as BBO-10203, suggesting its importance in future treatment regimens and the potential to reshape existing treatment landscapes.
- Clinical Trial Progress: Initial data from the KONQUER-101 trial indicate promising anti-tumor activity across various tumor types, including a 56% tumor reduction in a pancreatic cancer patient, with additional data expected in the second half of 2026.
- Selectivity and Resistance: BBO-11818 exhibits over 500-fold selectivity for KRAS compared to other RAS isoforms, highlighting its potential to overcome resistance mechanisms associated with existing KRAS inhibitors, potentially offering better tolerability and therapeutic outcomes for patients.
See More
